Yükleniyor... / Loading...
Clinical Intramuscular Gene Transfer Trial of rAAVrh74.MCK.Micro-Dystrophin to Patients With Duchenne Muscular Dystrophy
Bu çalışma, rAAVrh74.MCK.micro-Dystrophin adlı bir gen terapisinin kasa içine (intramüsküler) uygulanarak Duchenne musküler distrofi (Duchenne muscular dystrophy) hastalarındaki güvenliğini incelemiştir. Çalışmaya, Dystrophin mutasyonu doğrulanmış, tekerlekli sandalyeye bağımlı, 7 yaş ve üzeri erkek hastalar dahil edilmiştir. Çalışma Faz 1 aşamasında yürütülmüş ve tamamlanmıştır.
Yukarıdaki özet, resmî kaydın sade dile aktarılmış halidir. Orijinal İngilizce başlık referans için gösterilir.
Kriterler ClinicalTrials.gov kaydından orijinal İngilizce haliyle alınmıştır. Uygunluk kararını yalnızca deneyi yürüten ekip verebilir.
Inclusion Criteria: * Age 7 or older; must be wheelchair-dependent * Confirmed Dystrophin mutations based on mutation compatibility with micro-dys cDNA based on previously published methods. * Males of any ethnic group will be eligible. * Ability to cooperate with muscle testing. * Willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception (If appropriate). Exclusion Criteria: * Active viral infection based on clinical observations. * Symptoms or signs of cardiomyopathy, including: * Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs * Echocardiogram with ejection fraction below 40% * Serological evidence of HIV infection, or Hepatitis A, B or C infection * Diagnosis of (or ongoing treatment for) an autoimmune disease * Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer. * Subjects with AAVrh74 binding antibody titers ≥ 1:50 as determined by ELISA immunoassay. * Abnormal laboratory values in the clinically significant range as defined in protocol or based upon normal values in the Nationwide Children's Hospital Laboratory.